A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease

Alireza Faridar; Abdulmunaim M. Eid; Aaron D. Thome; Weihua Zhao; David R. Beers; Maria B. Pascual; Mohammad O. Nakawah; Gustavo C. Roman; Charles S. Davis; Michael Grundman; Joseph C. Masdeu; Stanley H. Appel

doi:10.1186/s40035-023-00387-5

Alireza Faridar, Abdulmunaim M. Eid, Aaron D. Thome, Weihua Zhao, David R. Beers, Maria B. Pascual, Mohammad O. Nakawah, Gustavo C. Roman, Charles S. Davis, Michael Grundman, Joseph C. Masdeu, Stanley H. Appel

Translational Neurodegeneration ›› 2023, Vol. 12 ›› Issue (0) : 54.

PDF(1973 KB)

Translational Neurodegeneration ›› 2023, Vol. 12 ›› Issue (0) : 54. DOI: 10.1186/s40035-023-00387-5

LETTER

A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2023, 12(0): 54 https://doi.org/10.1186/s40035-023-00387-5

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

Funding

RIGHTS & PERMISSIONS

PDF(1973 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Accepted	Published
2023-08-02	2023-11-06	2023-01-01
Issue Date
2023-11-16

Please choose a citation manager

Content to export